Scarica l'app Stockscreener
3.88
1.02%
-0.04
Pre-mercato:
3.88
Galmed Pharmaceuticals Ltd Borsa (GLMD) Ultime notizie
Galmed Pharmaceuticals Ltd. SEC Filing (Sep 4, 2026) - Stock Titan
Galmed Pharmaceuticals Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Galmed Pharmaceuticals Shareholders Approve All Proposals at September 3 AGM - TipRanks
Shareholders back every Galmed (NASDAQ: GLMD) proposal at September meeting - Stock Titan
Galmed Pharmaceuticals: Q2 Earnings Snapshot - kvue.com
Galmed Pharmaceuticals Reports $4.63 Million Net Loss Over First Half of 2026 (NASDAQ: GLMD) - Kalkine Media
Galmed Pharmaceuticals Posts Higher R&D Spend and Shrinking Cash in Q2 2026 - TipRanks
Equity deal could dilute Galmed (NASDAQ: GLMD) holders by nearly 40% - Stock Titan
Reverse split and cash strain leave Galmed (GLMD) below a proposed Nasdaq cutoff - Stock Titan
6-K: Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Galmed Pharmaceuticals (GLMD) delays annual meeting to Sept. 3 after low turnout - Stock Titan
Galmed Pharmaceuticals (GLMD) Retreats to $4.17 as Selling Pressure BuildsSynthetic Long - vinanet.vn
Galmed Pharmaceuticals Ltd expected to post a loss of $3.12 a shareEarnings Preview - TradingView
Galmed (GLMD): Slides 5.59% to $4.30 in the Current Update; Immediate View: the Current Price Sits Inside the Supplied Technical Range at the CloseDark Pool Volume - vinanet.vn
Galmed Pharmaceuticals Ltd.: Financial Data Forecasts Estimates and Expectations | GLMD | IL0011313900 - marketscreener.com
Galmed Pharmaceuticals completes 8-for-1 revers... - Pluang
Galmed completes colon tissue assessment study - grafa.com
Galmed completes feasibility study for colon tissue assessment tech By Investing.com - Investing.com Nigeria
Galmed’s Colospan Unit Reports Successful First-in-Human Study for New Colorectal Surgery Platform - TipRanks
Colospan completes successful study on new colo... - Pluang
Galmed completes feasibility study for colon tissue assessment tech - Investing.com
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology - PR Newswire
Galmed Reports Aramchol–Xtandi Combo Boosts Prostate Cancer Cell Death in Pre-Clinical Study - TipRanks
Galmed reports pre-clinical data on Aramchol-enzalutamide combo - Investing.com
Galmed reports pre-clinical data on Aramchol-enzalutamide combo By Investing.com - Investing.com UK
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models - Yahoo Finance Singapore
Galmed Pharmaceuticals to Enact 1-for-8 Reverse Share Split Effective August 19, 2026 - TipRanks
Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026 - Stock Titan
Galmed Pharmaceuticals (GLMD) Slips 6.1% to $0.56 as Selling Pressure IntensifiesIchimoku Kumo Twist - Vinanet
Galmed Pharmaceuticals (GLMD) Holds at $0.60 as Micro-Cap Biotech Trades Between Key LevelsPrice Action Signals - dars.gov.et
Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galmed Pharmaceuticals (GLMD) Rises 5.4% to $0.62, Approaching Key ResistanceOpening Range Breakout - vinanet.vn
GLMD Q1 2026 Earnings: Surprise Profit Beats Estimates as Shares Gain 5.4%Earnings Deceleration Risk - Vinanet
Galmed Pharmaceuticals Wins Nasdaq Extension to Regain $1 Bid Price Compliance - TipRanks
Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule - Stock Titan
Galmed Pharmaceuticals Ltd. (GLMD) Q1 2026 Earnings: Surprise Profit Driven by Expense Management and Non-Operating GainsEarnings Power Value - dars.gov.et
Galmed Pharmaceuticals Drops Yissum License to Sharpen Focus on Colospan and Aramchol - TipRanks
Galmed advances Parkinson’s drug formulation with higher CNS exposure - Investing.com
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market - PR Newswire
Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galmed Pharmaceuticals Ltd - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.602|Chg%:-0.004 - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.523|Chg%:-0.008 - TradingKey
Galmed Pharmaceuticals (GLMD) Slides 5.4%: Testing Key Support After Bearish MoveSymmetrical Triangle - vinanet.vn
Galmed Pharmaceuticals Ltd. Revenue Breakdown – NASDAQ:GLMD - TradingView
Galmed Pharmaceuticals Sets August 26, 2026 Annual Meeting to Approve Governance and Structural Changes - The Globe and Mail
GLMD Q2'26 Earnings: EPS estimate is (0.39) USD - TradingView
Galmed Pharmaceuticals (GLMD) sets 2026 AGM on name change and pay - Stock Titan
GLMD Q1 2026 Earnings: Stellar EPS Surprise Despite Revenue Absence and Stock DeclineMargin Compression Risk - vinanet.vn
Galmed unveils heart-targeted Aramchol in cardiac fibrosis push - Indian Pharma Post
Galmed Accelerates Heart Failure Innovation with Aramchol - t.co
Galmed develops heart-targeted formulation of Aramchol drug By Investing.com - Investing.com South Africa
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) - Yahoo Finance
Galmed develops heart-targeted formulation of Aramchol drug - Investing.com
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs - Stock Titan
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol - PR Newswire
Galmed Pharmaceuticals (GLMD) Slips 2.16% as Shares Test Key Support Near $0.47Low Vol ETF - po-news-eg.net
Galmed Pharmaceuticals (GLMD) Sheds 4.75% as Biotech Volatility Pressures Near SupportPrice Action Signals - dars.gov.et
Galmed Pharmaceuticals (GLMD) Holds Steady at $0.57: Consolidation Phase with Key Levels in FocusSkew Index - dars.gov.et
Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending - TipRanks
Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition - Stock Titan
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):